Indaptus Therapeutics’ (INDP) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Indaptus Therapeutics (NASDAQ:INDP) in a research note released on Monday morning, Benzinga reports. HC Wainwright currently has a $12.00 price objective on the stock. HC Wainwright also issued estimates for Indaptus Therapeutics’ Q1 2024 earnings at ($0.57) EPS, Q2 2024 earnings at ($0.60) EPS, Q4 2024 earnings at ($0.34) EPS, FY2024 earnings at ($1.83) EPS, Q1 2025 earnings at ($0.38) EPS, Q2 2025 earnings at ($0.37) EPS, Q3 2025 earnings at ($0.35) EPS, Q4 2025 earnings at ($0.35) EPS and FY2025 earnings at ($1.44) EPS.

Indaptus Therapeutics Trading Down 5.3 %

INDP stock opened at $2.52 on Monday. The firm’s 50-day moving average is $2.15 and its two-hundred day moving average is $2.11. The company has a market capitalization of $21.52 million, a price-to-earnings ratio of -1.37 and a beta of 1.28. Indaptus Therapeutics has a 52 week low of $1.56 and a 52 week high of $4.08.

Indaptus Therapeutics (NASDAQ:INDP) last posted its quarterly earnings data on Wednesday, March 13th. The company reported ($0.47) EPS for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.07. On average, equities research analysts predict that Indaptus Therapeutics will post -1.83 earnings per share for the current year.

Institutional Trading of Indaptus Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Vanguard Group Inc. boosted its stake in Indaptus Therapeutics by 18.7% during the first quarter. Vanguard Group Inc. now owns 242,235 shares of the company’s stock valued at $969,000 after buying an additional 38,216 shares in the last quarter. Northern Trust Corp bought a new stake in Indaptus Therapeutics in the first quarter worth about $41,000. State Street Corp acquired a new stake in Indaptus Therapeutics in the 1st quarter valued at about $78,000. Renaissance Technologies LLC bought a new position in shares of Indaptus Therapeutics during the 2nd quarter valued at about $51,000. Finally, Citadel Advisors LLC acquired a new position in shares of Indaptus Therapeutics in the 4th quarter worth approximately $29,000. Institutional investors own 7.06% of the company’s stock.

About Indaptus Therapeutics

Indaptus Therapeutics, Inc, a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial.